Home > > > > > Report Detail

Pulmonary Arterial Hypertension (PAH) - Market Insight, Epidemiology and Market Forecast - 2028

Publisher Name :
Date: 15-Jan-2019
No. of pages: 100
Delivery of the Report will take 2-3 working days once order is placed.

DelveInsight's "Pulmonary Arterial Hypertension (PAH) - Market Insight, Epidemiology and Market Forecast - 2028" report provides a detailed analysis of the Pulmonary Arterial Hypertension (PAH) epidemiology and market outlook for the 7MM.

Markets Covered

- United States

- EU5 (Germany, France, Italy, Spain, and the United Kingdom)

- Japan

Study Period: 2016-2028

Pulmonary Arterial Hypertension (PAH) Understanding and Treatment Algorithm

The market report provides the overview of the Pulmonary Arterial Hypertension (PAH) by providing the disease overview, definition, classification, symptoms, etiology, pathophysiology and diagnostic methods. It also covers the detailed treatment approaches and therapy areas under research and development for 7MM.

Pulmonary Arterial Hypertension (PAH) Epidemiology

The report provides a comprehensive account of the total patient pool, diagnosed cases and potential patient pool eligible for the treatment. It also includes the explanation of changing trends of epidemiology after evaluating numerous studies, survey reports and views of key opinion leaders. The Report provides the 10 years forecast from 2016 to 2028 segmented by seven major markets, enabling to understand the potential of the Pulmonary Arterial Hypertension (PAH) in the respective markets. The epidemiology data is presented with graphs and tables to provide a clear assessment of the landscape.

Pulmonary Arterial Hypertension (PAH) Product Profiles & Analysis

The drug chapter segment covers the complete analysis of marketed drugs and Phase III & late Phase II pipeline drugs. This division focuses on the recent breakthroughs like clinical development analysis, agreements and collaborations, clinical trial details, allotted designations, published results, pharmacological effects, patent expiry, and expected launch timings. Moreover, advantages and disadvantages of the therapy along with opinion of experts for marketed and emerging drugs are also provided.

Pulmonary Arterial Hypertension (PAH) Market Outlook

The report's market outlook delivers an understanding of the country-specific revenue and share by analyzing the performance of the current therapies and potential uptake of new products. The in-depth analysis helps to recognize the growing demand of the market by evaluating the annual cost of therapy, compliance rate, competition with other therapies, covered patient segment, impact of emerging technology in the forecast period. The views from the key opinion leaders adds more value to the analysis. This segment provides the relevant graphs and tables to have an effective outline of the Pulmonary Arterial Hypertension (PAH) market.

Pulmonary Arterial Hypertension (PAH) Market Share by Therapies

This division provides an understanding of the rate of drug uptake, drugs including both recently launched and those which show potential to get launched during the forecast period from 2016-2028. The analysis is based on patient uptake by therapies, sales projection of each drug by studying the reasons behind the maximal use of new drugs. A comparative analysis is also done on the basis of market share and size by assessing the drugs uptake to project the drug positioning in the market.

Pulmonary Arterial Hypertension (PAH) Report Insights

- Patient Population in Pulmonary Arterial Hypertension (PAH)

- Therapeutic Approaches in Pulmonary Arterial Hypertension (PAH)

- Pulmonary Arterial Hypertension (PAH) Pipeline Analysis

- Pulmonary Arterial Hypertension (PAH) Market Size and Trends

- Pulmonary Arterial Hypertension (PAH) Market Opportunities

- Impact of upcoming Therapies in Pulmonary Arterial Hypertension (PAH)

Pulmonary Arterial Hypertension (PAH) Report Key Strengths

- 10 Year Forecast

- 7MM Coverage

- Epidemiology Segmentation

- Drugs Uptake

- Highly Analyzed Market

- Key Cross Competition

Pulmonary Arterial Hypertension (PAH) Report Assessment

- Current Treatment Practices in Pulmonary Arterial Hypertension (PAH)

- Unmet Needs in Pulmonary Arterial Hypertension (PAH)

- Market Attractiveness

- Market Drivers and Barriers

Key Benefits

- The report will help to develop Business Strategies by understanding the trends shaping and driving the Pulmonary Arterial Hypertension (PAH) market

- Organize sales and marketing efforts by identifying the best opportunities for Pulmonary Arterial Hypertension (PAH) market

- To understand the future market competition in the Pulmonary Arterial Hypertension (PAH) market.

Pulmonary Arterial Hypertension (PAH) - Market Insight, Epidemiology and Market Forecast - 2028

Table of Contents

1. Report Introduction
2. Pulmonary Arterial Hypertension (PAH) Market Overview at a Glance
2.1. Market Share Distribution of Pulmonary Arterial Hypertension (PAH) in 2016
2.2. Market Share Distribution of Pulmonary Arterial Hypertension (PAH) in 2028
3. Disease Background and Overview: Pulmonary Arterial Hypertension (PAH)
3.1. Introduction
3.2. Symptoms
3.3. Etiology
3.4. Risk Factors
3.5. Pathophysiology
3.6. Diagnosis
3.7. Treatment
4. Epidemiology and Patient Population
4.1. Key Findings
4.2. Total Prevalent/ Incident Patient Population of Pulmonary Arterial Hypertension (PAH) in 7MM
4.3. Total Prevalent Patient Population of Pulmonary Arterial Hypertension (PAH) in 7MM - By Countries
5. Epidemiology of Pulmonary Arterial Hypertension (PAH) by Countries
5.1. United States
5.1.1. Assumptions and Rationale
5.1.2. Prevalent/Incident Cases of the Pulmonary Arterial Hypertension (PAH)
5.1.3. Sub-Type Specific cases of the Pulmonary Arterial Hypertension (PAH) *
5.1.4. Sex- Specific Cases of the Pulmonary Arterial Hypertension (PAH) *
5.1.5. Diagnosed Cases of the Pulmonary Arterial Hypertension (PAH)
5.1.6. Treatable Cases of the Pulmonary Arterial Hypertension (PAH)
5.2. EU5
5.3. Assumptions and Rationale
5.4. Germany
5.4.1. Assumptions and Rationale
5.4.2. Prevalent/Incident Cases of the Pulmonary Arterial Hypertension (PAH)
5.4.3. Sub-Type Specific cases of the Pulmonary Arterial Hypertension (PAH) *
5.4.4. Sex- Specific Cases of the Pulmonary Arterial Hypertension (PAH) *
5.4.5. Diagnosed Cases of the Pulmonary Arterial Hypertension (PAH)
5.4.6. Treatable Cases of the Pulmonary Arterial Hypertension (PAH)
5.5. France
5.5.1. Assumptions and Rationale
5.5.2. Prevalent/Incident Cases of the Pulmonary Arterial Hypertension (PAH)
5.5.3. Sub-Type Specific cases of the Pulmonary Arterial Hypertension (PAH) *
5.5.4. Sex- Specific Cases of the Pulmonary Arterial Hypertension (PAH) *
5.5.5. Diagnosed Cases of the Pulmonary Arterial Hypertension (PAH)
5.5.6. Treatable Cases of the Pulmonary Arterial Hypertension (PAH)
5.6. Italy
5.6.1. Assumptions and Rationale
5.6.2. Prevalent/Incident Cases of the Pulmonary Arterial Hypertension (PAH)
5.6.3. Sub-Type Specific cases of the Pulmonary Arterial Hypertension (PAH) *
5.6.4. Sex- Specific Cases of the Pulmonary Arterial Hypertension (PAH) *
5.6.5. Diagnosed Cases of the Pulmonary Arterial Hypertension (PAH)
5.6.6. Treatable Cases of the Pulmonary Arterial Hypertension (PAH)
5.7. Spain
5.7.1. Assumptions and Rationale
5.7.2. Prevalent/Incident Cases of the Pulmonary Arterial Hypertension (PAH)
5.7.3. Sub-Type Specific cases of the Pulmonary Arterial Hypertension (PAH) *
5.7.4. Sex- Specific Cases of the Pulmonary Arterial Hypertension (PAH) *
5.7.5. Diagnosed Cases of the Pulmonary Arterial Hypertension (PAH)
5.7.6. Treatable Cases of the Pulmonary Arterial Hypertension (PAH)
5.8. United Kingdom
5.8.1. Assumptions and Rationale
5.8.2. Prevalent/Incident Cases of the Pulmonary Arterial Hypertension (PAH)
5.8.3. Sub-Type Specific cases of the Pulmonary Arterial Hypertension (PAH) *
5.8.4. Sex- Specific Cases of the Pulmonary Arterial Hypertension (PAH) *
5.8.5. Diagnosed Cases of the Pulmonary Arterial Hypertension (PAH)
5.8.6. Treatable Cases of the Pulmonary Arterial Hypertension (PAH)
5.9. Japan
5.9.1. Assumptions and Rationale
5.9.2. Prevalent/Incident Cases of the Pulmonary Arterial Hypertension (PAH)
5.9.3. Sub-Type Specific cases of the Pulmonary Arterial Hypertension (PAH) *
5.9.4. Sex- Specific Cases of the Pulmonary Arterial Hypertension (PAH) *
5.9.5. Diagnosed Cases of the Pulmonary Arterial Hypertension (PAH)
5.9.6. Treatable Cases of the Pulmonary Arterial Hypertension (PAH)
6. Current Treatment & Medical practices
6.1. Treatment Algorithm
6.2. Treatment Guidelines
7. Unmet Needs of the Pulmonary Arterial Hypertension (PAH)
8. Marketed Therapies
8.1. Drug A: Company 1
8.1.1. Drug Description
8.1.2. Mechanism of Action
8.1.3. Regulatory Milestones
8.1.4. Advantages & Disadvantages
8.1.5. Product Profile
8.2. Drug B: Company 2
8.2.1. Drug Description
8.2.2. Mechanism of Action
8.2.3. Regulatory Milestones
8.2.4. Advantages & Disadvantages
8.2.5. Product Profile
9. Pipeline Therapies - At a glance
10. Key Cross Competition
11. Emerging Therapies for Pulmonary Arterial Hypertension (PAH)
11.1. Drug C: Company 3
11.1.1. Drug Description
11.1.2. Clinical Trials Details
11.1.3. Safety and Efficacy Profile
11.1.4. Advantages & Disadvantages
11.1.5. Pipeline Development Activities
11.1.6. Product Profile
11.2. Drug D: Company 4
11.2.1. Drug Description
11.2.2. Clinical Trials Details
11.2.3. Safety and Efficacy Profile
11.2.4. Advantages & Disadvantages
11.2.5. Pipeline Development Activities
11.2.6. Product Profile
12. Pulmonary Arterial Hypertension (PAH) : 7MM Market Analysis
12.1. 7MM Market Size of Pulmonary Arterial Hypertension (PAH)
12.2. 7MM Percentage Share of drugs marketed for Pulmonary Arterial Hypertension (PAH)
12.3. 7MM Market Sales of Pulmonary Arterial Hypertension (PAH) by Products
13. Pulmonary Arterial Hypertension (PAH) : Country-Wise Market Analysis
13.1. United States
13.1.1. Market Size of Pulmonary Arterial Hypertension (PAH) in United States
13.1.2. Percentage Share of drugs marketed for Pulmonary Arterial Hypertension (PAH) in United States
13.1.3. Market Sales of Pulmonary Arterial Hypertension (PAH) by Products in United States
13.1.4. Analysis of Upcoming Therapies and their Impact on the Market
13.2. EU-5
13.2.1. Germany
13.2.1.1. Market Size of Pulmonary Arterial Hypertension (PAH) in Germany
13.2.1.2. Percentage Share of drugs marketed for Pulmonary Arterial Hypertension (PAH) in Germany
13.2.1.3. Market Sales of Pulmonary Arterial Hypertension (PAH) by Products in Germany
13.2.1.4. Analysis of Upcoming Therapies and their Impact on the Market
13.2.2. France
13.2.2.1. Market Size of Pulmonary Arterial Hypertension (PAH) in France
13.2.2.2. Percentage Share of drugs marketed for Pulmonary Arterial Hypertension (PAH) in France
13.2.2.3. Market Sales of Pulmonary Arterial Hypertension (PAH) by Products in France
13.2.2.4. Analysis of Upcoming Therapies and their Impact on the Market
13.2.3. Italy
13.2.3.1. Market Size of Pulmonary Arterial Hypertension (PAH) in Italy
13.2.3.2. Percentage Share of drugs marketed for Pulmonary Arterial Hypertension (PAH) in Italy
13.2.3.3. Market Sales of Pulmonary Arterial Hypertension (PAH) by Products in Italy
13.2.3.4. Analysis of Upcoming Therapies and their Impact on the Market
13.2.4. Spain
13.2.4.1. Market Size of Pulmonary Arterial Hypertension (PAH) in Spain
13.2.4.2. Percentage Share of drugs marketed for Pulmonary Arterial Hypertension (PAH) in Spain
13.2.4.3. Market Sales of Pulmonary Arterial Hypertension (PAH) by Products in Spain
13.2.4.4. Analysis of Upcoming Therapies and their Impact on the Market
13.2.5. United Kingdom
13.2.5.1. Market Size of Pulmonary Arterial Hypertension (PAH) in United Kingdom
13.2.5.2. Percentage Share of drugs marketed for Pulmonary Arterial Hypertension (PAH) in United Kingdom
13.2.5.3. Market Sales of Pulmonary Arterial Hypertension (PAH) by Products in United Kingdom
13.2.5.4. Analysis of Upcoming Therapies and their Impact on the Market
13.3. Japan
13.3.1. Market Size of Pulmonary Arterial Hypertension (PAH) in Japan
13.3.2. Percentage Share of drugs marketed for Pulmonary Arterial Hypertension (PAH) in Japan
13.3.3. Market Sales of Pulmonary Arterial Hypertension (PAH) by Products in Japan
13.3.4. Analysis of Upcoming Therapies and their Impact on the Market
14. Market Drivers
15. Market Barriers
16. Appendix
17. Report Methodology
17.1. Sources
18. DelveInsight Capabilities
19. Disclaimer
20. About DelveInsight

*Indication Specific

List of Tables

Table 1: Total Prevalent/Incident Cases of the Pulmonary Arterial Hypertension (PAH) in 7MM
Table 2: Total Prevalent/Incident Cases of the Pulmonary Arterial Hypertension (PAH) in 7MM by Countries
Table 3: Prevalent/Incident Cases of the Pulmonary Arterial Hypertension (PAH) in United States (2016-2028)
Table 4: Sub-Type Specific cases of the Pulmonary Arterial Hypertension (PAH) in United States (2016-2028)
Table 5: Sex- Specific Cases of the Pulmonary Arterial Hypertension (PAH) in United States (2016-2028)
Table 6: Diagnosed Cases of the Pulmonary Arterial Hypertension (PAH) in United States (2016-2028)
Table 7: Treatable Cases of the Pulmonary Arterial Hypertension (PAH) in United States (2016-2028)
Table 8: Prevalent/Incident Cases of the Pulmonary Arterial Hypertension (PAH) in Germany (2016-2028)
Table 9: Sub-Type Specific cases of the Pulmonary Arterial Hypertension (PAH) in Germany (2016-2028)
Table 10: Sex- Specific Cases of the Pulmonary Arterial Hypertension (PAH) in Germany (2016-2028)
Table 11: Diagnosed Cases of the Pulmonary Arterial Hypertension (PAH) in Germany (2016-2028)
Table 12: Treatable Cases of the Pulmonary Arterial Hypertension (PAH) in Germany (2016-2028)
Table 13: Prevalent/Incident Cases of the Pulmonary Arterial Hypertension (PAH) in France (2016-2028)
Table 14: Sub-Type Specific cases of the Pulmonary Arterial Hypertension (PAH) in France (2016-2028)
Table 15: Sex- Specific Cases of the Pulmonary Arterial Hypertension (PAH) in France (2016-2028)
Table 16: Diagnosed Cases of the Pulmonary Arterial Hypertension (PAH) in France (2016-2028)
Table 17: Treatable Cases of the Pulmonary Arterial Hypertension (PAH) in France (2016-2028)
Table 18: Prevalent/Incident Cases of the Pulmonary Arterial Hypertension (PAH) in Italy (2016-2028)
Table 19: Sub-Type Specific cases of the Pulmonary Arterial Hypertension (PAH) in Italy (2016-2028)
Table 20: Sex- Specific Cases of the Pulmonary Arterial Hypertension (PAH) in Italy (2016-2028)
Table 21: Diagnosed Cases of the Pulmonary Arterial Hypertension (PAH) in Italy (2016-2028)
Table 22: Treatable Cases of the Pulmonary Arterial Hypertension (PAH) in Italy (2016-2028)
Table 23: Prevalent/Incident Cases of the Pulmonary Arterial Hypertension (PAH) in Spain (2016-2028)
Table 24: Sub-Type Specific cases of the Pulmonary Arterial Hypertension (PAH) in Spain (2016-2028)
Table 25: Sex- Specific Cases of the Pulmonary Arterial Hypertension (PAH) in Spain (2016-2028)
Table 26: Diagnosed Cases of the Pulmonary Arterial Hypertension (PAH) in Spain (2016-2028)
Table 27: Treatable Cases of the Pulmonary Arterial Hypertension (PAH) in Spain (2016-2028)
Table 28: Prevalent/Incident Cases of the Pulmonary Arterial Hypertension (PAH) in UK (2016-2028)
Table 29: Sub-Type Specific cases of the Pulmonary Arterial Hypertension (PAH) in UK (2016-2028)
Table 30: Sex- Specific Cases of the Pulmonary Arterial Hypertension (PAH) in UK (2016-2028)
Table 31: Diagnosed Cases of the Pulmonary Arterial Hypertension (PAH) in UK (2016-2028)
Table 32: Treatable Cases of the Pulmonary Arterial Hypertension (PAH) in UK (2016-2028)
Table 33: Prevalent/Incident Cases of the Pulmonary Arterial Hypertension (PAH) in Japan (2016-2028)
Table 34: Sub-Type Specific cases of the Pulmonary Arterial Hypertension (PAH) in Japan (2016-2028)
Table 35: Sex- Specific Cases of the Pulmonary Arterial Hypertension (PAH) in Japan (2016-2028)
Table 36: Diagnosed Cases of the Pulmonary Arterial Hypertension (PAH) in Japan (2016-2028)
Table 37: Treatable Cases of the Pulmonary Arterial Hypertension (PAH) in Japan (2016-2028)
Table 38: Marketed Therapies
Table 39: Emerging Therapies
Table 40: Key Cross Competition
Table 41:7MM- Market Size of Pulmonary Arterial Hypertension (PAH) in USD MM (2016-2028)
Table 42:7MM- Market Share Pulmonary Arterial Hypertension (PAH) by Therapies in USD MM (2016-2028)
Table 43:7MM- Market Sales of Pulmonary Arterial Hypertension (PAH) by Therapies in USD MM (2016-2028)
Table 44: United States-Market Size of Pulmonary Arterial Hypertension (PAH) in USD MM (2016-2028)
Table 45: United States-Market Share Pulmonary Arterial Hypertension (PAH) by Therapies in USD MM (2016-2028)
Table 46: United States-Market Sales of Pulmonary Arterial Hypertension (PAH) by Therapies in USD MM (2016-2028)
Table 47: Germany-Market Size of Pulmonary Arterial Hypertension (PAH) in USD MM (2016-2028)
Table 48: Germany-Market Share Pulmonary Arterial Hypertension (PAH) by Therapies in USD MM (2016-2028)
Table 49: Germany-Market Sales of Pulmonary Arterial Hypertension (PAH) by Therapies in USD MM (2016-2028)
Table 50: France-Market Size of Pulmonary Arterial Hypertension (PAH) in USD MM (2016-2028)
Table 51: France-Market Share Pulmonary Arterial Hypertension (PAH) by Therapies in USD MM (2016-2028)
Table 52: France-Market Sales of Pulmonary Arterial Hypertension (PAH) by Therapies in USD MM (2016-2028)
Table 53: Italy-Market Size of Pulmonary Arterial Hypertension (PAH) in USD MM (2016-2028)
Table 54: Italy-Market Share Pulmonary Arterial Hypertension (PAH) by Therapies in USD MM (2016-2028)
Table 55: Italy-Market Sales of Pulmonary Arterial Hypertension (PAH) by Therapies in USD MM (2016-2028)
Table 56: Spain-Market Size of Pulmonary Arterial Hypertension (PAH) in USD MM (2016-2028)
Table 57: Spain-Market Share Pulmonary Arterial Hypertension (PAH) by Therapies in USD MM (2016-2028)
Table 58: Spain-Market Sales of Pulmonary Arterial Hypertension (PAH) by Therapies in USD MM (2016-2028)
Table 59:UK-Market Size of Pulmonary Arterial Hypertension (PAH) in USD MM (2016-2028)
Table 60:UK-Market Share Pulmonary Arterial Hypertension (PAH) by Therapies in USD MM (2016-2028)
Table 61:UK-Market Sales of Pulmonary Arterial Hypertension (PAH) by Therapies in USD MM (2016-2028)
Table 62: Japan-Market Size of Pulmonary Arterial Hypertension (PAH) in USD MM (2016-2028)
Table 63: Japan-Market Share Pulmonary Arterial Hypertension (PAH) by Therapies in USD MM (2016-2028)
Table 64: Japan-Market Sales of Pulmonary Arterial Hypertension (PAH) by Therapies in USD MM (2016-2028)

List of Figures

Figure 1: Total Prevalent/Incident Cases of the Pulmonary Arterial Hypertension (PAH) in 7MM
Figure 2: Total Prevalent/Incident Cases of the Pulmonary Arterial Hypertension (PAH) in 7MM by Countries
Figure 3: Prevalent/Incident Cases of the Pulmonary Arterial Hypertension (PAH) in United States (2016-2028)
Figure 4: Sub-Type Specific cases of the Pulmonary Arterial Hypertension (PAH) in United States (2016-2028)
Figure 5: Sex- Specific Cases of the Pulmonary Arterial Hypertension (PAH) in United States (2016-2028)
Figure 6: Diagnosed Cases of the Pulmonary Arterial Hypertension (PAH) in United States (2016-2028)
Figure 7: Treatable Cases of the Pulmonary Arterial Hypertension (PAH) in United States (2016-2028)
Figure 8: Prevalent/Incident Cases of the Pulmonary Arterial Hypertension (PAH) in Germany (2016-2028)
Figure 9: Sub-Type Specific cases of the Pulmonary Arterial Hypertension (PAH) in Germany (2016-2028)
Figure 10: Sex- Specific Cases of the Pulmonary Arterial Hypertension (PAH) in Germany (2016-2028)
Figure 11: Diagnosed Cases of the Pulmonary Arterial Hypertension (PAH) in Germany (2016-2028)
Figure 12: Treatable Cases of the Pulmonary Arterial Hypertension (PAH) in Germany (2016-2028)
Figure 13: Prevalent/Incident Cases of the Pulmonary Arterial Hypertension (PAH) in France (2016-2028)
Figure 14: Sub-Type Specific cases of the Pulmonary Arterial Hypertension (PAH) in France (2016-2028)
Figure 15: Sex- Specific Cases of the Pulmonary Arterial Hypertension (PAH) in France (2016-2028)
Figure 16: Diagnosed Cases of the Pulmonary Arterial Hypertension (PAH) in France (2016-2028)
Figure 17: Treatable Cases of the Pulmonary Arterial Hypertension (PAH) in France (2016-2028)
Figure 18: Prevalent/Incident Cases of the Pulmonary Arterial Hypertension (PAH) in Italy (2016-2028)
Figure 19: Sub-Type Specific cases of the Pulmonary Arterial Hypertension (PAH) in Italy (2016-2028)
Figure 20: Sex- Specific Cases of the Pulmonary Arterial Hypertension (PAH) in Italy (2016-2028)
Figure 21: Diagnosed Cases of the Pulmonary Arterial Hypertension (PAH) in Italy (2016-2028)
Figure 22: Treatable Cases of the Pulmonary Arterial Hypertension (PAH) in Italy (2016-2028)
Figure 23: Prevalent/Incident Cases of the Pulmonary Arterial Hypertension (PAH) in Spain (2016-2028)
Figure 24: Sub-Type Specific cases of the Pulmonary Arterial Hypertension (PAH) in Spain (2016-2028)
Figure 25: Sex- Specific Cases of the Pulmonary Arterial Hypertension (PAH) in Spain (2016-2028)
Figure 26: Diagnosed Cases of the Pulmonary Arterial Hypertension (PAH) in Spain (2016-2028)
Figure 27: Treatable Cases of the Pulmonary Arterial Hypertension (PAH) in Spain (2016-2028)
Figure 28: Prevalent/Incident Cases of the Pulmonary Arterial Hypertension (PAH) in UK (2016-2028)
Figure 29: Sub-Type Specific cases of the Pulmonary Arterial Hypertension (PAH) in UK (2016-2028)
Figure 30: Sex- Specific Cases of the Pulmonary Arterial Hypertension (PAH) in UK (2016-2028)
Figure 31: Diagnosed Cases of the Pulmonary Arterial Hypertension (PAH) in UK (2016-2028)
Figure 32: Treatable Cases of the Pulmonary Arterial Hypertension (PAH) in UK (2016-2028)
Figure 33: Prevalent/Incident Cases of the Pulmonary Arterial Hypertension (PAH) in Japan (2016-2028)
Figure 34: Sub-Type Specific cases of the Pulmonary Arterial Hypertension (PAH) in Japan (2016-2028)
Figure 35: Sex- Specific Cases of the Pulmonary Arterial Hypertension (PAH) in Japan (2016-2028)
Figure 36: Diagnosed Cases of the Pulmonary Arterial Hypertension (PAH) in Japan (2016-2028)
Figure 37: Treatable Cases of the Pulmonary Arterial Hypertension (PAH) in Japan (2016-2028)
Figure 38: Marketed Therapies
Figure 39: Emerging Therapies
Figure 40: Key Cross Competition
Figure 41:7MM- Market Size of Pulmonary Arterial Hypertension (PAH) in USD MM (2016-2028)
Figure 42:7MM- Market Share Pulmonary Arterial Hypertension (PAH) by Therapies in USD MM (2016-2028)
Figure 43:7MM- Market Sales of Pulmonary Arterial Hypertension (PAH) by Therapies in USD MM (2016-2028)
Figure 44: United States-Market Size of Pulmonary Arterial Hypertension (PAH) in USD MM (2016-2028)
Figure 45: United States-Market Share Pulmonary Arterial Hypertension (PAH) by Therapies in USD MM (2016-2028)
Figure 46: United States-Market Sales of Pulmonary Arterial Hypertension (PAH) by Therapies in USD MM (2016-2028)
Figure 47: Germany-Market Size of Pulmonary Arterial Hypertension (PAH) in USD MM (2016-2028)
Figure 48: Germany-Market Share Pulmonary Arterial Hypertension (PAH) by Therapies in USD MM (2016-2028)
Figure 49: Germany-Market Sales of Pulmonary Arterial Hypertension (PAH) by Therapies in USD MM (2016-2028)
Figure 50: France-Market Size of Pulmonary Arterial Hypertension (PAH) in USD MM (2016-2028)
Figure 51: France-Market Share Pulmonary Arterial Hypertension (PAH) by Therapies in USD MM (2016-2028)
Figure 52: France-Market Sales of Pulmonary Arterial Hypertension (PAH) by Therapies in USD MM (2016-2028)
Figure 53: Italy-Market Size of Pulmonary Arterial Hypertension (PAH) in USD MM (2016-2028)
Figure 54: Italy-Market Share Pulmonary Arterial Hypertension (PAH) by Therapies in USD MM (2016-2028)
Figure 55: Italy-Market Sales of Pulmonary Arterial Hypertension (PAH) by Therapies in USD MM (2016-2028)
Figure 56: Spain-Market Size of Pulmonary Arterial Hypertension (PAH) in USD MM (2016-2028)
Figure 57: Spain-Market Share Pulmonary Arterial Hypertension (PAH) by Therapies in USD MM (2016-2028)
Figure 58: Spain-Market Sales of Pulmonary Arterial Hypertension (PAH) by Therapies in USD MM (2016-2028)
Figure 59:UK-Market Size of Pulmonary Arterial Hypertension (PAH) in USD MM (2016-2028)
Figure 60:UK-Market Share Pulmonary Arterial Hypertension (PAH) by Therapies in USD MM (2016-2028)
Figure 61:UK-Market Sales of Pulmonary Arterial Hypertension (PAH) by Therapies in USD MM (2016-2028)
Figure 62: Japan-Market Size of Pulmonary Arterial Hypertension (PAH) in USD MM (2016-2028)
Figure 63: Japan-Market Share Pulmonary Arterial Hypertension (PAH) by Therapies in USD MM (2016-2028)
Figure 64: Japan-Market Sales of Pulmonary Arterial Hypertension (PAH) by Therapies in USD MM (2016-2028)

  • Global Pulmonary Arterial Hypertension (Pah) Medicine Industry Research Report, In-depth Analysis of Current Status and Outlook of Key Countries 2023-2028
    Published: 04-Jan-2024        Price: US 3380 Onwards        Pages: 103
    Market Overview of Global Pulmonary Arterial Hypertension (Pah) Medicine market: According to our latest research, the global Pulmonary Arterial Hypertension (Pah) Medicine market looks promising in the next 5 years. As of 2022, the global Pulmonary Arterial Hypertension (Pah) Medicine market was estimated at USD XX million, and it's anticipated to reach USD XX million in 2028, with a CAGR of XX% during the forecast years. This report covers a research time span from 2018 to ......
  • Global Nifedipine Industry Research Report, In-depth Analysis of Current Status and Outlook of Key Countries 2023-2028
    Published: 04-Jan-2024        Price: US 3380 Onwards        Pages: 102
    Market Overview of Global Nifedipine market: According to our latest research, the global Nifedipine market looks promising in the next 5 years. As of 2022, the global Nifedipine market was estimated at USD XX million, and it's anticipated to reach USD XX million in 2028, with a CAGR of XX% during the forecast years. This report covers a research time span from 2018 to 2028, and presents a deep and comprehensive analysis of the global Nifedipine market, with a systematical de......
  • Global Amlodipine Besylate Market Research Report 2024
    Published: 04-Jan-2024        Price: US 2900 Onwards        Pages: 115
    The Amlodipine Besylate market size, estimations, and forecasts are provided in terms of sales volume (K Units) and revenue ($ millions), considering 2023 as the base year, with history and forecast data for the period from 2019 to 2030. This report segments the global Amlodipine Besylate market comprehensively. Regional market sizes, concerning products by Type, by Application, and by players, are also provided. For a more in-depth understanding of the market, the report provides profil......
  • Pulmonary Arterial Hypertension (PAH) Drugs - Global Market Insights and Sales Trends 2024
    Published: 25-Dec-2023        Price: US 3350 Onwards        Pages: 112
    The global Pulmonary Arterial Hypertension (PAH) Drugs market size is expected to reach US$ million by 2029, growing at a CAGR of % from 2023 to 2029. The market is mainly driven by the significant applications of Pulmonary Arterial Hypertension (PAH) Drugs in various end use industries. The expanding demands from the Hospitals, Clinics and Other,, are propelling Pulmonary Arterial Hypertension (PAH) Drugs market. Inhalation, one of the segments analysed in this report, is projected to record % ......
  • Captopril API - Global Market Insights and Sales Trends 2024
    Published: 25-Dec-2023        Price: US 3350 Onwards        Pages: 100
    The global Captopril API market size is expected to reach US$ million by 2029, growing at a CAGR of % from 2023 to 2029. The market is mainly driven by the significant applications of Captopril API in various end use industries. The expanding demands from the Captopril Tablet, Compound Captopril Tablet and Captopril Injection,, are propelling Captopril API market. 98% Captopril API, one of the segments analysed in this report, is projected to record % CAGR and reach US$ million by the end of the......
  • Telmisartan - Global Market Insights and Sales Trends 2024
    Published: 21-Dec-2023        Price: US 3350 Onwards        Pages: 107
    The global Telmisartan market size is expected to reach US$ 3631.3 million by 2029, growing at a CAGR of 3.4% from 2023 to 2029. The market is mainly driven by the significant applications of Telmisartan in various end use industries. The expanding demands from the Hospital, Clinic and Others,, are propelling Telmisartan market. Injection, one of the segments analysed in this report, is projected to record % CAGR and reach US$ million by the end of the analysis period. Growth in the Freeze-Dried......
  • Global Ambrisentan Professional Survey Report 2023, Forecast to 2028
    Published: 20-Dec-2023        Price: US 3280 Onwards        Pages: 106
    Ambrisentan is a drug indicated for use in the treatment of pulmonary hypertension. The peptide endothelin constricts muscles in blood vessels, increasing blood pressure. Ambrisentan, which relaxes those muscles, is an endothelin receptor antagonist, and is selective for the type A endothelin receptor. Our market research experts provide qualitative and quantitative analysis of the market based on involving economic and non-economic factors in the same report with market value (million US......
  • Global Ambrisentan Market Research Report 2023, Forecast to 2028
    Published: 20-Dec-2023        Price: US 2680 Onwards        Pages: 132
    Ambrisentan is a drug indicated for use in the treatment of pulmonary hypertension. The peptide endothelin constricts muscles in blood vessels, increasing blood pressure. Ambrisentan, which relaxes those muscles, is an endothelin receptor antagonist, and is selective for the type A endothelin receptor. Our market research experts provide qualitative and quantitative analysis of the market based on involving economic and non-economic factors in the same report with market value (million US......
  • Global Amlodipine Besylate Professional Survey Report 2023, Forecast to 2028
    Published: 20-Dec-2023        Price: US 3280 Onwards        Pages: 133
    Our market research experts provide qualitative and quantitative analysis of the market based on involving economic and non-economic factors in the same report with market value (million USD) data for each segment and sub-segment. This way, clients can achieve all their goals while taking advantage of emerging opportunities. Technological advancements, new product launches, and market capital flows are compared across scenarios to demonstrate their impact over the forecast period. D......
    • SERVICES
    Value for Money
    We believe in "optimum utilization of available budget and resources". While servicing our clients' (your) market research requirements, we keep the same approach in focus to help you get the best value for your $$s.
    Ever Growing Inventory
    Ranging from the smallest feasible / required data (datasheets, data facts, SWOT analysis, company profiles, etc) to full research reports that help you make decisions, our inventory is updated almost on a daily basis with the latest industry reports from domain experts that track more than 5000 niche sectors.
    One Stop Solution
    Need a custom research report on medical devices market? Require all available business intelligence on 3D printing industry? Exploring F&B sector of a particular country/region? RnRMarketResearch.com is your one-stop-solution to all market intelligence needs. We not only offer custom research and consulting services, we also "bundle" reports to meet your needs and help you fetch the data analysis you require for your business.
    Dedicated Client Engagement
    Not limited to only "finding" relevant reports for you, our client engagement team dedicates its efforts to understand your "business need" and accordingly maps available research data to help you move forward. Call "your" client engagement executive any time of your day and get your questions answered in order to make the correct business decision.
    Saving Time and Efforts
    Simply share your research requirement details with us and let us do all the hard work to find required intelligence for you. When you add up our "one stop solution" and "dedicated client engagement" services mentioned above, you obviously know the time and effort saving you do by working with us.
    Payment Flexibility
    Working with Fortune 500 organizations, we understand the importance of being flexible for payments. Share your payment terms with us and we will surely match up to them to ensure you get access to required business intelligence data without having to wait for the payment to be done.
    Post-Purchase Research Support
    Have questions after reading a report / datasheet bought through us? Not sure about the methodology used for data available in the research? Talk to us / Share your questions with us and if required, we will connect you with the analyst(s)/author(s) of the report(s) and ensure you get satisfactory answers for the same. Need more data / analysis / report(s) on the topic of your research/project? The RnRMarketResearch.com team is here for you 24X7 to support you with your post-purchase requirements. Subscription Offers & Packages (Get in touch with us for more details - [email protected] / +1 888 391 5441 )
    • Ad Hoc
    • Pay - as - you - go / Bucket Subscriptions
    • Fixed Cost for #of reports
    • Customize / Personalize as per your needs